Table 4. Local Health Agency Reporting Requirements

III (,III,ã O-III + (,III,S III,ã	Amebiasis Anthrax Aseptic meningitis, viral Basidiobolomycosis Botulism Brucellosis	III III III III III III	Hantavirus infection Hemolytic uremic syndrome Hepatitis A Hepatitis B and Hepatitis D Hepatitis C Hepatitis E	III (,III,S (,III,S III O-+ (,III	Rocky Mountain spotted fever Rubella (German measles) Rubella syndrome, congenital Salmonellosis Scabies Severe  acute  respiratory   syn-
					drome
III	Campylobacteriosis	None	Herpes genitalis	III	Shigellosis
III	Chagas infection and related disease (American Trypano- somiasis)	III	Human Immunodeficiency Virus (HIV) infection and related dis- ease	(,III	Smallpox
III	Chancroid         (Haemophilus ducreyi)	III	Influenza-associated mortality in a child	O-III	Streptococcal  Group  A  infec- tion
5-day only	Chlamydia   infection,    sexu- ally transmitted	+	Kawasaki syndrome	III	Streptococcal Group B infec- tion in an infant younger than 90 days of age
),III	Cholera	III	Legionellosis        (Legionnaires’ disease)	+	Streptococcus          pneumoniae infection
O-III	Coccidioidomycosis    (Valley Fever)	III	Leptospirosis	III,O-III	Syphilis
III	Colorado tick fever	III,ã	Listeriosis	III	Taeniasis
O-+	Conjunctivitis: acute	III	Lyme disease	III	Tetanus
+	Creutzfeldt-Jakob disease	III	Lymphocytic choriomeningitis	III	Toxic shock syndrome
III	Cryptosporidiosis	III	Malaria	III	Trichinosis
III	Cyclospora infection	(,III,S	Measles (rubeola)	III,ã	Tuberculosis
+	Cysticercosis	III,ã	Melioidosis	(,III,ã	Tularemia
III	Dengue	(,III,ã	Meningococcal invasive disease	III	Typhoid fever
O-III	Diarrhea, nausea, or vomiting	(,III,S	Mumps	III	Typhus fever
(,III	Diphtheria	O-III	Norovirus	),III	Unexplained death with a his- tory of fever
III	Ehrlichioses (Ehrlichiosis and Anaplasmosis)	5-day only	Pediculosis (lice infestation)	III	Vaccinia-related adverse event
(,III	Emerging or exotic disease	III	Pertussis (whooping cough)	(,III,ã	Vancomycin-resistant or Vanco- mycin-intermediate Staphylo- coccus aureus
),III	Encephalitis: viral or parasitic	(,III,ã	Plague	),III,ã	Vancomycin-resistant Staphylo- coccus epidermidis
III	Enterohemorrhagic       Esche- richia coli	(,III,S	Poliomyelitis	+	Varicella (chickenpox)
III	Enterotoxigenic   Escherichia coli	III	Psittacosis (ornithosis)	III	Vibrio infection
O-III	Giardiasis	),III	Q Fever	(,III,S	Viral hemorrhagic fever
5-day only	Gonorrhea	(,III	Rabies in a human	III	West   Nile    virus-related   syn- dromes
III	Haemophilus              influenzae: invasive disease	III	Relapsing fever (borreliosis)	),III	Yellow fever
+	Hansen’s disease (Leprosy)	+	Reye syndrome	),III,ã	Yersiniosis    (enteropathogenic Yersinia)

Unless otherwise specified, notify the Department within five working days after receiving a report under R9-6-202 or R9-6-203.

Key:

( Notify the Department within 24 hours after receiving a report under R9-6-202 or R9-6-203.

) Notify the Department within one working day after receiving a report under R9-6-202 or R9-6-203.

III   Submit an epidemiologic investigation report within 30 calendar days after receiving a report under R9-6-202 or R9-6-203 or notification by the Depart- ment.

+ Submit an epidemiologic investigation report within 60 calendar days after receiving a report under R9-6-202 or R9-6-203 or notification by the Depart-

ment.

ã     Ensure that an isolate from a case is submitted to the Arizona State Laboratory.

S      Ensure that specimens from a case, as specified by the Department, are submitted to the Arizona State Laboratory.

O     Submit a report after conducting an epidemiological investigation of an outbreak.

Historical Note

New Table 4 made by final rulemaking at 14 A.A.R. 1502, effective April 1, 2008 (Supp. 08-2).